In a melanoma mouse model, the combination therapy significantly decreased tumor burden over either HDAC6i or anti-PD-1 treatments, increased cytotoxic T cells in the TME, and reduced the anti-inflammatory properties of tumor associated macrophages37. Here, PDCD1 is linked to neoplasm.